International Journal of Radiation Oncology*Biology*Physics
Physics ContributionEstimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial
Cited by (0)
Emma Hall and Sarah Gulliford made equal contributions to this work.
Disclosures: D.B. reports grants from Cancer Research UK, during the conduct of the study. D.D. reports personal fees from The Institute of Cancer Research, during the conduct of the study, and a patent (EP1933709B1) issued. A.T. reports grants, personal fees, and other from Elekta, grants from Accuray, grants from Varian, other from Janssen, other from Astellas, other from Bayer, other from Ferring, other from Genesis health care, outside the submitted work.
E.H. reports grants from Cancer Research UK, during the conduct of the study; grants from Accuray, grants from Varian Medical Systems, grants and nonfinancial support from Astra Zeneca, grants and nonfinancial support from Janssen-Cilag, grants and nonfinancial support from Bayer, grants from Roche Products Ltd, grants and nonfinancial support from Merck Sharp & Dohm, grants from Prostate Cancer UK, and grants and nonfinancial support from Aventis Pharma Limited (Sanofi), outside the submitted work.
Deidentified individual participant data, together with a data dictionary defining each field in the set, will be made available to other researchers on request. The Institute of Cancer Research (ICR) Clinical Trials and Statistics Unit (CTSU) supports wider dissemination of information from the research it conducts and increased cooperation between investigators. Trial data are obtained, managed, stored, shared, and archived according to ICR-CTSU standard operating procedures to ensure the enduring quality, integrity and utility of the data. Formal requests for data sharing are considered in line with ICR-CTSU procedures, with due regard given to funder and sponsor guidelines. Requests are via a standard proforma describing the nature of the proposed research and extent of data requirements. Data recipients are required to enter a formal data sharing agreement, which describes the conditions for release and requirements for data transfer, storage, archiving, publication, and Intellectual Property. Requests are reviewed by the Trial Management Group (TMG) in terms of scientific merit and ethical considerations, including patients’ consent. Data sharing is undertaken if proposed projects have a sound scientific or patients’ benefit rationale, as agreed by the TMG and approved by the Independent Data Monitoring and Steering Committee, as required. Restrictions relating to patients’ confidentiality and consent will be limited by aggregating and anonymizing identifiable patients’ data. Additionally, all indirect identifiers that could lead to deductive disclosures will be removed in line with Cancer Research UK data sharing guidelines.